Page 9 - Biontech Se News Today

PacWest shares surge after the regional lender says its reducing its dividend, Catalent tumbles after delaying the release of its earnings report, and Zscaler rises after boosting guidance.

BioNTechs first-quarter revenue falls from a year earlier as demand for Covid-19 vaccines wanes but still tops analysts estimates.

As the biotech reports first-quarter earnings, the focus will be on Modernas pipeline of future vaccines and cancer treatments and whether they can fill the hole left by dwindling Covid vaccine sales. .

What to expect from the pharma giants Q1 earnings report.

The FDA also authorized a second Omicron-targeting booster shot for high-risk groups

Investegate announcements from BioNTech SE, BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets...

Analysts’ price target changes for Tuesday, March 28th: Covestro (ETR:1COV) was given a €46.00 ($49.46) price target by analysts at Deutsche Bank Aktiengesellschaft. adidas (FRA:ADS) was given a €170.00 ($182.80) price target by analysts at Deutsche Bank Aktiengesellschaft. Aroundtown (ETR:AT1) was given a €2.60 ($2.80) price target by analysts at Warburg Research. Basf (ETR:BAS) was […]

The German biotech that partnered with Pfizer to develop a Covid-19 vaccine expects fewer vaccinations and lowered levels of boosting this year.

The shares initially fell by 6.4% to an intraday low of $119.98 a share before recovering most of those losses in late morning trading.